| Summary: | Prevention and treatment efforts of cancer is becoming increasingly crucial
given the type and level of the higher incidence. The research of anticancer drug
compounds is still being conducted and has been related to drugs that have a high
selectivity and specificity towards cancer cells. Pentagamavunon-0 (PGV-0) as a
synthetic compound that was developed from curcumin as a lead compounds have
been studied as an inhibitor of cyclooxygenase (COX) activity with no specific
measurement (Nurrochmad, 1999), cytotoxicity against myeloma cells (Nurrochmad,
2001) and test the cytotoxicity against Raji cells , HeLa cells and myeloma cells are
found PGV-0 has potential as an anticancer drug better than curcumin (Da�i, 2003).
Research was conducted to determine the potential antiproliferative several
compounds derived PGV-0 on HeLa cells obtained by synthesis using concentrated
sulfuric acid catalyst.
Synthesis of PGV-0 compounds and its analogues with concentrated sulfuric
acid catalyst is done in the absence of solvent, the solvent methanol and the solvent 2-
Butanol with refluxed generate the amount of different yield. Purification of
compounds synthesized carried by washing with hot water (90 ° C) and
recrystallization with a suitable solvent. Purity analysis conducted with melting point
test and Thin Layer Chromatography (TLC). The characterization of the synthesized
compounds by the method of structure elucidation carried using a IR
spectrophotometer, 1H-NMR spectrometer and a mass spectrometer. Cytotoxic test
was conducted by MTT test. And the data were analyzed by probit analysis and
doubling time analysis.
Cytotoxic assay committed against HeLa cells to acquire data in the form of
potential cytotoxic IC50 values. PGV-0 compound and its analogs are cytotoxic
against HeLa cells with IC50 values respectively as follows: 0,055 mM (PGV-0),
0,656 mM (MT-OH), 5,376 mM (MT-Cl), 5,723 mM [MT-N(CH3)2]. Analysis
doubling time is only committed against compound PGV-0
|
|---|